Eli Lilly seeks EUA from US Food and Drug Administration for Covid-19 antibody treatment
5 years ago 1 min read
Eli Lilly and Company’s monoclonal antibody combination therapy reduced virus levels, hospitalizations and emergency room visits in patients with mild-to-moderate Covid-19, the pharmaceutical company said Wednesday.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push